Ishita Drugs Faces Financial Stagnation Amid Limited Growth and Debt Challenges
Ishita Drugs & Industries has recently experienced a change in its financial evaluation, reflecting its current position in the pharmaceuticals sector. The company reported flat financial performance for the quarter ending December 2024, with modest growth in net sales and operating profit over the past five years.
Ishita Drugs & Industries has recently undergone an adjustment in evaluation, reflecting a shift in its financial standing within the pharmaceuticals and drugs sector. The company, categorized as a microcap, has reported flat financial performance for the quarter ending December 2024. This stagnation is underscored by a modest average Return on Equity (ROE) of 8.34%, indicating challenges in long-term fundamental strength.Over the past five years, Ishita Drugs has experienced limited growth, with net sales increasing at an annual rate of 0.73% and operating profit at 7.86%. Additionally, the company's ability to manage its debt appears constrained, as evidenced by a below-average EBIT to interest ratio of 0.79.
Despite these challenges, the stock has shown some resilience, generating an 18.93% return over the past year, while profits have risen by 21%. The stock is currently trading at a discount compared to its peers, with a Price to Book Value ratio of 2.5, suggesting an attractive valuation relative to historical averages.
For those interested in further insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
